All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Treating elderly and frail patients with MM: Cure versus disease control
Bookmark this article
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Vincent Rajkumar, Mayo Clinic, Rochester, US, discussed: Treating elderly and frail patients with MM: Cure versus disease control.
Treating elderly and frail patients with MM: Cure versus disease control
In this presentation, Rajkumar discusses the current standard of treatment for elderly, frail patients (VRd−bortezomib, lenalidomide, dexamethasone) and regimens that are currently being tested across various clinical trials to improve upon this standard, such as replacement of bortezomib with carfilzomib or daratumumab, and quadruplet combinations. He then discusses if a cure is really feasible for MM, and highlights some key considerations for a true cure; when treatment is given for a finite time and the disease never returns. He concludes with his recommendations for assessing MM cure in future trials.
Treating elderly and frail patients with MM: Cure versus disease control
Treating elderly and frail patients with MM: Cure versus disease control
Vincent Rajkumar's slides are available as a downloadable resource below.
Download the slides here!Find below links to the other talks from the symposium:
'Does 'cure' have a different meaning in MM?' presented by Mohamad Mohty.
'Is the treatment of high-risk smoldering multiple myeloma (SMM) the way for achieving the cure?' presented by María-Victoria Mateos.
'Is transplantation still relevant? If yes, in which context?' presented by Sagar Lonial.
'Roundtable discussion' with María-Victoria Mateos, Mohamad Mohty, and Sagar Lonial.
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox